key: cord-0821202-s6uo7tff
authors: Azam Ansari, Mohammad; Mohammad Sajid Jamal, Qazi; Rehman, Suriya; Almatroudi, Ahmad; Alzohairy, Mohammad A.; Alomary, Mohammad N.; Tripathi, Takshashila; Alharbi, Ali H; Farooq Adil, Syed; Khan, Mujeeb; Shaheer Malik, M.
title: TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): potential therapeutic intervention to combat COVID-19
date: 2020-10-01
journal: Arabian journal of chemistry
DOI: 10.1016/j.arabjc.2020.09.037
sha: d87812c9d796633b918d4013975ccfbc8615bdee
doc_id: 821202
cord_uid: s6uo7tff

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese city of Wuhan has caused around 906,092 deaths and 28,040,853 confirmed cases worldwide (WHO, 11 September, 2020). In a life-threatening situation, where there is no specific and licensed anti-COVID-19 vaccine or medicine available; the repurposed drug might act as a silver bullet. Currently, more than 211 vaccines, 80 antibodies, 31 antiviral drugs, 35 cell-based, 6 RNA-based and 131 other drugs are in clinical trials. It is therefore utter need of the hour to develop an effective drug that can be used for the treatment of COVID-19 before a vaccine can be developed. One of the best-characterized and attractive drug targets among coronaviruses is the main protease (3CLpro). Therefore, the current study focuses on the molecular docking analysis of TAT-peptide47–57 (GRKKRRQRRRP)-conjugated repurposed drugs (i.e., lopinavir, ritonavir, favipiravir, and hydroxychloroquine) with SARS-CoV-2 main protease (3CLpro) to discover potential efficacy of TAT-peptide (TP) - conjugated repurposing drugs against SARS-CoV-2. The molecular docking results validated that TP-conjugated ritonavir, lopinavir, favipiravir, and hydroxychloroquine have superior and significantly enhanced interactions with the target SARS-CoV-2 main protease. In-silico approach employed in this study suggests that the combination of the drug with TP is an excelling alternative to develop a novel drug for the treatment of SARS-CoV-2 infected patients. The development of TP based delivery of repurposing drugs might be an excellent approach to enhance the efficacy of the existing drugs for the treatment of COVID-19. The predictions from the results obtained provide invaluable information that can be utilized for the choice of candidate drugs for in vitro, in vivo and clinical trials. The outcome from this work prove crucial for exploring and developing novel cost-effective and biocompatible TP conjugated anti-SARS-CoV-2 therapeutic agents in immediate future.

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in Chinese Currently, no vaccine or medicine has been developed that can be used for the treatment of SARS-106 CoV-2 infections, therefore, the repurposed drug could act as a brilliant alternative with potential 107 to combat the disease effectively (Saha et al., 2020b) . Though, preclinical and clinical trials are 108 required to ensure their effectiveness, such treatment might be better and promising than a placebo. and antimalarial drugs. The 3D modelled structure of TP used in this study was generated by PEP-232 FOLD3.5 (Figure 2) . Further, the 3D modeled structure of TP was validated by MolProbity tool 233 integrated in structure assessment module of SwissModel server. It was observed that number of 234 residues found in the favored region was ~100.0% and no residues were found in Ramachandran

Outliers and Rotamer Outliers regions ( Figure 3A) . The MolProbity Score was 0.50 and 236 QMEAN4 score was less than <1 as compared with standard ideal value that should be between Figure 7C) . 254 We postulated that after conjugating repurposed drug to TAT-peptide, the binding affinity was 255 enhanced to counter the COVID-19 protease. Further, it was also hypothesized that the TP 256 conjugated repurposing drugs interact more strongly and efficiently than drugs without TAT 257 conjugate. In the present study, the obtained results support our experimental hypothesis. The 258 molecular docking study showed that the interaction of repurposed drugs ritonavir, lopinavir, 259 favipiravir and hydroxychloroquine (without TP conjugation) formed 5, 4, 8 and 2 H-bonds, 260 respectively, when docked with COVID-19 main protease (Table S1, S3; Fig 4ab, 5ab,6ab, 7ab) . 261 The visualization of full 3D structures of COVID-19 main protease docked with the individual 262 drugs without TP was shown in supplementary figure (S1-S5). The observed binding energy score 263 was -9.16 kcal/mol for ritonavir, -7.57 kcal/mol for lopinavir, -4.23 kcal/mol for favipiravir and - Table S1 ). The favipiravir, an antiviral drug that inhibits viral RNA-dependent RNA-268 polymerase is currently in Phase 2, 3 and 4 for treatment of COVID-19, has the binding energy for 269 inhibition of Mpro of SARS-CoV-2 (i.e., -4.23 kcal/mol, Table S1 ) are weaker binders than (Figure 4D,5D,6D,7D; Table S2 ). It has been observed that the efficacy 284 of repurposed drugs have been enhanced after conjugating with TP when compared to drug without 285 TP. When TP was interacted with ritonavir, lopinavir, favipiravir, and hydroxychloroquine only 4, 286 1, 3, and 2 H-bond were formed (Table S3) . However, when TP-conjugated ritonavir, lopinavir, 287 favipiravir, and hydroxychloroquine drug complex were docked with COVID-19 main protease 8, 288 10, 10, and 15 H-bonds were formed which are comparatively much higher than that of the drug 289 without the TP (Figure 4D,5D,6D,7D; Table S2, S3) . After comparing the molecular docking 290 data of drugs without TP with COVID-19 protease (Figure 4ab, 5ab, 6ab,7ab; Table S1 ) and TP-291 conjugated drug complex (Figure 4D,5D,6D,7D; Table S2 ), it has been found that TP-conjugated 292 drugs interacted most efficiently with COVID-19 main protease (Table S3) 

The antimicrobial and antiviral applications of cell-456 penetrating peptides

Coronavirus infections-more than just the 459 common cold

Molecular mechanism of HIV-1 TAT peptide and its conjugated 462 gold nanoparticles translocating across lipid membranes

Current scenario 465 of COVID-19 in pediatric age group and physiology of immune and thymus response

Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in COVID-19

Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know 472

SymmDock: servers for rigid and symmetric docking

Virtual Screening based prediction of potential drugs for COVID-19

Cell-penetrating peptides in vaccine delivery: facts, challenges 481 and perspectives

Cell penetrating peptides in 483 preclinical and clinical cancer diagnosis and therapy

CHARMM general force field: A 487 force field for drug-like molecules compatible with the CHARMM all-atom additive biological 488 force fields

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 491 (2019-nCoV) in vitro

Clinical characteristics and therapeutic 494 procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and 495 Western medicine treatment

Toward Nanotechnology-Enabled Approaches 499 against the COVID-19 Pandemic

SWISS-MODEL: 502 homology modelling of protein structures and complexes

Nelfinavir was predicted to 505 be a potential inhibitor of 2019-nCov main protease by an integrative approach combining 506 homology modelling, molecular docking and binding free energy calculation

MERS, SARS and other coronaviruses as causes of pneumonia

/mol CC1=C(C(=CC=C1)C)OCC( =O)NC(CC2=CC=CC=C2)C (CC(CC3=CC=CC=C3)NC( =O)C(C(C)C)N4CCCNC4= /mol CC(C)C1=NC(=CS1)CN(C)

CC(=CC2=NC=C1)Cl)CCO

Gaurav, C., Marc, J.M., Sourav, K., Vianni, C., Deepa, G., Sergio, O., 2020. Nanotechnology for 390 COVID-19: Therapeutics and Vaccine Research. ACS Nano.